Clinical Guidelines


D. Technical report

Appendix D

Technical report

GUIDELINE UPDATES - This guideline was last updated 7/1/2022

This Technical Report accompanies the Clinical management guidelines for the prevention of cervical cancer, developed by Cancer Council Australia. 

It outlines the guideline development process and methodology, lists the clinical questions, provides all accompanying NHMRC Statement Forms, the detailed technical documentation for each question and the risk of bias assessment tools used to assess the included literature as a result of a systematic review. 


Guideline Development Process

Figure 1. Overview review process

Literature review protocol algorithm

Clinical question list

NHMRC Evidence statements forms

Systematic review, modelling and literature review reports

Management of oncogenic HPV test results - Oncogenic HPV types not 16/18

Colposcopy - Normal colposcopic findings following LBC prediction of LSIL or HSIL

Colposcopy - Type 3 TZ (previously termed ‘unsatisfactory’) colposcopy following LBC prediction of LSIL or HSIL

Management of histologically confirmed low-grade squamous abnormalities

Management of histologically confirmed high-grade squamous abnormalities

Treatment of HSIL

Test of Cure after treatment for HSIL (CIN2/3)

Management of glandular abnormalities

Investigation of cytological glandular abnormalities

Follow-up after excisional treatment for AIS

Screening in Aboriginal and Torres Strait Islander women

Screening after total hysterectomy

Screening in pregnancy

Screening in women who have experienced early sexual activity or have been victims of sexual abuse

Screening in immune-deficient women

Screening in DES-exposed women

Investigation of abnormal vaginal bleeding

Cohort studies (risk factors) risk of bias assessment tool

WEBSITE UPDATES - This website was last updated 7/1/2022